Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics Inc (NQ: MYGN )

16.61 -0.16 (-0.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 541,969
Open 16.78
Bid (Size) 16.11 (1)
Ask (Size) 17.12 (1)
Prev. Close 16.77
Today's Range 16.42 - 16.80
52wk Range 13.92 - 24.21
Shares Outstanding 81,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Issues 2022 Environmental, Social and Governance Report
From Myriad Genetics, Inc.
Via GlobeNewswire

Performance

YTD
+8.85%
+8.85%
1 Month
-8.33%
-8.33%
3 Month
-26.99%
-26.99%
6 Month
-29.97%
-29.97%
1 Year
-13.22%
-13.22%

More News

Read More
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Earnings Scheduled For August 3, 2023
Via Benzinga
Preview: Myriad Genetics's Earnings
Via Benzinga
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
From Myriad Genetics, Inc.
Via GlobeNewswire
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Host Investor Day on September 19, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
From Myriad Genetics, Inc.
Via GlobeNewswire
Intermountain Health and Myriad Genetics Participate in ComboMATCH
Via PRUnderground
Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces New $90 Million Asset-Based Credit Facility
From Myriad Genetics, Inc.
Via GlobeNewswire
Cramer Calls Tech Giant A 'Great' Long-Term Play, But In The Short Term It's Just 'Too Hot'
Via Benzinga
3 Gene Testing Stocks to Buy Before They Take Off
Via InvestorPlace
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Participate in Goldman Sachs Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.